The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. 2011

Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
Department of Cardiovascular Surgery, Tayfur Ata Sokmen Medical Faculty, Mustafa Kemal University, Hatay, Turkey. mehmetguzeloglu @ hotmail.com

Acute renal failure due to ischemia-reperfusion (I/R) injury is a common complication in cardiovascular surgery. We determined the influence of tadalafil on renal injury in a renal I/R model in rats. For this purpose, 21 male Wistar albino rats were separated into 3 groups: sham, placebo and tadalafil. A right nephrectomy was performed, and the left renal pedicles were occluded for 60 min and reperfused for 60 min in the placebo and tadalafil groups. A single dose of tadalafil (10 mg/kg) through an orogastric tube was administered to the tadalafil group. Tubular atrophy with acute inflammation in renal histology, total oxidant status (TOS) and total antioxidant status (TAS) were determined in tissue homogenates. Compared to the tadalafil group, tubular atrophy and acute inflammation was significant in the placebo group. TAS levels were significantly higher in the tadalafil group compared to the placebo (p = 0.01) and sham groups (p = 0.04). While TOS levels were significantly higher in the placebo group (p = 0.03), tadalafil did not significantly alter the TOS levels. The beneficial effects of tadalafil can be attributed to its protective effects on renal tubular cells and inhibition of leukocyte infiltration in renal tissue. We think that tadalafil treatment has an important role in reducing renal injury resulting from renal I/R.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002243 Carbolines A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. Carboline,Pyrido(4,3-b)Indole,Beta-Carbolines,Pyrido(4,3-b)Indoles,Beta Carbolines
D000068581 Tadalafil A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION. Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-,Cialis,IC 351,IC-351,IC351
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D001284 Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. Atrophies

Related Publications

Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
September 2015, The Kaohsiung journal of medical sciences,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
August 2011, Bosnian journal of basic medical sciences,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
March 2014, Acta neurologica Belgica,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
July 2012, Journal of pediatric surgery,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
April 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
January 2016, Transplantation proceedings,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
October 2004, Acta pharmacologica Sinica,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
November 2013, Experimental and therapeutic medicine,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
January 2011, Renal failure,
Mehmet Guzeloglu, and Fatih Yalcinkaya, and Soner Atmaca, and Alper Bagriyanik, and Suleyman Oktar, and Oguz Yuksel, and Iyad Fansa, and Eyup Hazan
October 2018, Yonsei medical journal,
Copied contents to your clipboard!